A Sudan Airways flight from Port Sudan touched down in the capital, marking a tentative step toward reconnecting a nation fractured by conflict.
Prominent Venezuelan human rights defender Javier Tarazona has been released after over four years in detention on charges widely condemned as politically motivated, as the government announces a new amnesty law and the U.S. re-engages diplomatically.
Costa Ricans cast ballots Sunday in an election defined by soaring narco-violence, with ruling party candidate Laura Fernandez, promising a Bukele-style crackdown, favored to win. The vote signals a potential rightward shift and constitutional showdown in a nation struggling with its transformation into a major drug trafficking hub.
Apple posts its strongest revenue growth in years, driven by a surprising iPhone resurgence and robust performance in China. Yet, the stock's muted reaction highlights investor focus on its premium valuation.
Salesforce expands its enterprise footprint with a landmark $5.6 billion defense contract and a new role in an AI-driven wildfire response initiative, signaling a strategic push into mission-critical government and infrastructure sectors.
Allegion (NYSE: ALLE) is accelerating its strategic shift toward integrated smart security platforms, emphasizing digital credentials, connected locks, and cloud-based access control to meet growing demand from commercial and institutional clients.
Atkore International is set to report its quarterly earnings Tuesday morning. Investors will be watching closely to see if the company can overcome recent headwinds in the electrical systems sector and meet Wall Street's forecasts.
Electronic Arts (EA) is set to report its fourth-quarter financial results after Tuesday's market close, with Wall Street anticipating a significant revenue rebound. The report comes at a pivotal moment for the gaming sector, which has faced mixed signals from consumers and a volatile market.
Aerospace and defense supplier TransDigm prepares to release its fourth-quarter results before market open on Tuesday, with analysts anticipating double-digit revenue growth and steady performance in a buoyant sector.
Mortgage insurer Enact Holdings (ACT) reports quarterly results Tuesday, with investors eyeing its performance in a volatile economic climate. Analysts expect modest revenue growth, but broader sector headwinds could weigh on outlook.
Archer-Daniels-Midland (ADM) is set to report Q4 earnings Tuesday morning. Analysts project a slight revenue dip, but investor sentiment remains cautiously optimistic as the agribusiness leader navigates a volatile global market.
Benchmark Electronics (NYSE:BHE) is set to report Q4 earnings after Tuesday's market close, with analysts forecasting a return to revenue growth. The electronics manufacturing services provider enters the report on a strong note, having outperformed expectations last quarter.
As Jack Henry & Associates (JKHY) prepares to announce its fiscal fourth-quarter results, the financial technology sector watches closely. The report could set the tone for peers in a market segment recently under pressure.
Two teens have filed a federal lawsuit against Saint Ann's School, claiming administrators failed to act on multiple red flags about a former teacher who coerced nude photos from them and later threatened to distribute the images.
Liam Conejo Ramos, whose detention with his father sparked national outcry, is back in Minnesota following a federal judge's order for their release from a Texas facility.
As artificial intelligence drives an unprecedented surge in electricity demand, one utility company—Constellation Energy—is uniquely positioned with its vast nuclear fleet to meet the need, turning an industry-wide bottleneck into a significant growth opportunity.
As a significant equity rotation takes hold in early 2026, shifting focus from growth to value, dividend-focused ETFs are emerging as key beneficiaries for investors seeking yield and stability.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.
